SCHEMBL4055464

SCHEMBL4055464

COc1ccc(-c2nc3ncc(-c4cccc5ccccc45)cc3[nH]2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 4/20 0.60
IKBKE Q14164 13/20 0.53
TBK1 Q9UHD2 13/20 0.53
AURKB Q96GD4 8/20 0.53
CDK2 P24941 1/20 0.53
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
PKM P14618 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TNKS O95271 1/20 0.44
GUSB P08236 1/20 0.44
PARP1 P09874 1/20 0.44
CASP3 P42574 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
TNKS2 Q9H2K2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4053861 0.90 AURKA (0.59) AURKAIKBKETBK1AURKBCDK2
SCHEMBL4057426 0.87 AURKA (0.48) AURKAALDH1A1GUSB
SCHEMBL4049957 0.86 AURKA (0.44) AURKAIKBKETBK1AURKBCDK2
SCHEMBL4058430 0.85 AURKA (0.61) AURKAIKBKETBK1AURKBCDK2
SCHEMBL4060342 0.85 PDE5A (0.57) AURKAPARP1
SCHEMBL4050460 0.83 NOS3 (0.49) AURKANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL13607910 0.82 RAB9A (0.50) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL4052372 0.81 AURKA (0.69) AURKAIKBKETBK1AURKBCDK2
SCHEMBL4052431 0.79 IDO1 (0.50) AURKAKDM4EALDH1A1MEN1KMT2A
SCHEMBL4055186 0.77 KDM4E (0.46) AURKAIKBKETBK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B AURKA 247/4885IKBKE 129/4885TBK1 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.